Abstract
Aptamers are a special class of nucleic acid molecules that are beginning to be investigated for clinical use. These small RNA/DNA molecules can form secondary and tertiary structures capable of specifically binding proteins or other cellular targets; they are essentially a chemical equivalent of antibodies. Aptamers have the advantage of being highly specific, relatively small in size, and non-immunogenic. Since the discovery of aptamers in the early 1990s, great efforts have been made to make them clinically relevant for diseases like cancer, HIV, and macular degeneration. In the last two decades, many aptamers have been clinically developed as inhibitors for targets such as vascular endothelial growth factor (VEGF) and thrombin. The first aptamer based therapeutic was FDA approved in 2004 for the treatment of age-related macular degeneration and several other aptamers are currently being evaluated in clinical trials. With advances in targeted-therapy, imaging, and nanotechnology, aptamers are readily considered as potential targeting ligands because of their chemical synthesis and ease of modification for conjugation. Preclinical studies using aptamer-siRNA chimeras and aptamer targeted nanoparticle therapeutics have been very successful in mouse models of cancer and HIV. In summary aptamers are in several stages of development, from pre-clinical studies to clinical trials and even as FDA approved therapeutics. In this review, we will discuss the current state of aptamers in clinical trials as well as some promising aptamers in pre-clinical development.
Keywords: Aptamers, clinical trial, imaging, nanoparticle, oligonucleotides, SELEX, siRNA, target therapy
Current Medicinal Chemistry
Title: Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Volume: 18 Issue: 27
Author(s): X. Ni, M. Castanares, A. Mukherjee and S.E. Lupold
Affiliation:
Keywords: Aptamers, clinical trial, imaging, nanoparticle, oligonucleotides, SELEX, siRNA, target therapy
Abstract: Aptamers are a special class of nucleic acid molecules that are beginning to be investigated for clinical use. These small RNA/DNA molecules can form secondary and tertiary structures capable of specifically binding proteins or other cellular targets; they are essentially a chemical equivalent of antibodies. Aptamers have the advantage of being highly specific, relatively small in size, and non-immunogenic. Since the discovery of aptamers in the early 1990s, great efforts have been made to make them clinically relevant for diseases like cancer, HIV, and macular degeneration. In the last two decades, many aptamers have been clinically developed as inhibitors for targets such as vascular endothelial growth factor (VEGF) and thrombin. The first aptamer based therapeutic was FDA approved in 2004 for the treatment of age-related macular degeneration and several other aptamers are currently being evaluated in clinical trials. With advances in targeted-therapy, imaging, and nanotechnology, aptamers are readily considered as potential targeting ligands because of their chemical synthesis and ease of modification for conjugation. Preclinical studies using aptamer-siRNA chimeras and aptamer targeted nanoparticle therapeutics have been very successful in mouse models of cancer and HIV. In summary aptamers are in several stages of development, from pre-clinical studies to clinical trials and even as FDA approved therapeutics. In this review, we will discuss the current state of aptamers in clinical trials as well as some promising aptamers in pre-clinical development.
Export Options
About this article
Cite this article as:
Ni X., Castanares M., Mukherjee A. and Lupold S.E., Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons, Current Medicinal Chemistry 2011; 18 (27) . https://dx.doi.org/10.2174/092986711797189600
DOI https://dx.doi.org/10.2174/092986711797189600 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reperfusion Therapies in Acute Ischemic Stroke
Recent Patents on CNS Drug Discovery (Discontinued) Prophylactic Vaccine Approach for Colon and Pancreatic Cancers: Present and Future
Current Medicinal Chemistry Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Long-term Outcomes of Mitral Valve Repair Versus Replacement for Degenerative Disease: A Systematic Review
Current Cardiology Reviews Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications
Current Pharmaceutical Design A Review of QSAR studies to Discover New Drug-like Compounds Actives Against Leishmaniasis and Trypanosomiasis
Current Topics in Medicinal Chemistry Metabolomics and Heart Diseases: From Basic to Clinical Approach
Current Medicinal Chemistry The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews MicroRNA Regulation and Role in Stem Cell Maintenance, Cardiac Differentiation and Hypertrophy
Current Molecular Medicine Conjugation of Resveratrol with RGD and KGD Derivatives
Protein & Peptide Letters Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy
Current Cardiology Reviews Future of Cardiac Pacemaker – an Update of Biological Pacemaker Patents
Recent Patents on Biomedical Engineering (Discontinued) Multi-target Activities of Selected Alkaloids and Terpenoids
Mini-Reviews in Organic Chemistry Vesicle Trafficking, Autophagy and Nanoparticles: A Brief Review
Current Nanomedicine Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials
Reviews on Recent Clinical Trials Predictive Factors of follow-up Non-attendance and Mortality Among Adults with Type 2 Diabetes Mellitus- an Analysis of the Malaysian Diabetes Registry 2009
Current Diabetes Reviews Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Serum Specific Vasopressin-Degrading Activity is Related to Blood Total Cholesterol Levels in Men but not in Women
Medicinal Chemistry Pathophysiology of Myocardial Infarction and Acute Management Strategies
Cardiovascular & Hematological Agents in Medicinal Chemistry Systematic Review of the Role of Microparticles in Systemic Sclerosis
Current Rheumatology Reviews